Q2 2026 saw strong commercial and financial performance, with proprietary product net sales up 34% year-over-year and robust growth across sleep, psychiatry, and addiction portfolios. The orexin pipeline advanced with positive clinical data, and the LUMRYZ integration drove further momentum.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.